Nirvana Life Sciences Inc.
NIRV
CNSX
| 07/31/2025 | 04/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -72.19% | 172.95% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -70.04% | 153.41% | |||
| Operating Income | 70.04% | -153.41% | |||
| Income Before Tax | 77.77% | -114.39% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 77.77% | -114.39% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 100.00% | -350.00% | |||
| Net Income | 77.84% | -115.88% | |||
| EBIT | 70.04% | -153.41% | |||
| EBITDA | -- | -165.20% | |||
| EPS Basic | 95.16% | -115.65% | |||
| Normalized Basic EPS | 93.55% | -115.28% | |||
| EPS Diluted | 95.16% | -115.65% | |||
| Normalized Diluted EPS | 93.55% | -115.28% | |||
| Average Basic Shares Outstanding | 373.19% | 0.00% | |||
| Average Diluted Shares Outstanding | 373.19% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||